Home » News » Industry Specific Issues

Industry Specific Issues

Telix Pharmaceuticals Achieves Successful Australian TGA Approval for Prostate Cancer Imaging

November 2nd, 2021

Melbourne-based Telix Pharmaceuticals Ltd has today reported the receipt of approval from the Australian TGA for its prostate cancer imaging product, Illuccix. Iluccix, after radiolabeling with gallium-68, is the first commercially approved PSMA-PET imaging agent available in Australia. Telix Pharmaceuticals has noted that the TGA approval was an important milestone as it looks to make other regulatory submissions across the Asia Pacific. Telix Pharmaceuticals has invested an enormous amount in R&D expenditure to reach this achievement, and are one of […]

Read More

Australian Based Immunetep Ltd (ASX:IMM) receives $3.4M AUD in French R&D Tax Incentives

September 30th, 2021

ASX listed, Sydney based company Immunetep Ltd recently announced that it has received a €2,126,617 (around A$3,400,000) payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). A similar magnitude payment was received in the previous year. The payment relates to activity the company is conducting in Paris to develop its novel Immunotherapy treatments. Immunetep Ltd also registers activities under the Australian R&D Tax Incentive and has previously reported the following receipts: YE 30 June 2018 […]

Read More

Imdex Ltd posts strong FY21 result leveraging R&D Investment

August 30th, 2021

Imdex Limited (ASX: IMD) is a WA-based company providing technology and equipment for the mining industry. The company offers a range of products and services, including: Drilling optimisation products; Rock knowledge sensors; Real time data and analytics solutions; Imdex Limited’s FY21 results were well received by the ASX, and concludes a year in which the company’s share price has almost doubled. An emphasis within the company’s results presentation released in August was the company’s R&D investment during the FY21 period. The […]

Read More

Government Discussion Paper and Consultation on Patent Box for Medical and Biotechnology Sectors

July 19th, 2021

In the May federal budget, the Australian Government announced that it will introduce a patent box for eligible income associated with new patents in the medical and biotechnology sectors. The patent box will apply to companies for income years commencing on or after 1 July 2022, and for new Australian patents since budget night.   The aim of such a policy is to encourage companies to base their medical and biotechnology R&D activity in Australia and to retain associated patent […]

Read More

Categories

Archives